• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    7/18/23 9:06:07 AM ET
    $ARDS
    $BPTS
    $CVM
    $EUDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDS alert in real time by email

    Gainers

    • Biophytis (NASDAQ:BPTS) shares increased by 45.2% to $3.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.9 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) shares rose 34.98% to $0.35. The market value of their outstanding shares is at $12.8 million.
    • Hyperfine (NASDAQ:HYPR) stock moved upwards by 19.65% to $2.8. The market value of their outstanding shares is at $199.0 million.
    • Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 17.09% to $1.79. The market value of their outstanding shares is at $204.2 million.
    • Genprex (NASDAQ:GNPX) shares increased by 10.93% to $1.04. The company's market cap stands at $54.0 million.
    • Lantern Pharma (NASDAQ:LTRN) shares rose 10.11% to $5.55. The company's market cap stands at $60.2 million.

    Losers

    • 9 Meters Biopharma (NASDAQ:NMTR) stock fell 69.6% to $0.19 during Tuesday's pre-market session. The company's market cap stands at $2.7 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares declined by 30.68% to $5.22. The company's market cap stands at $8.6 million.
    • Masimo (NASDAQ:MASI) shares declined by 28.78% to $104.81. The company's market cap stands at $5.5 billion.
    • CEL-SCI (AMEX:CVM) shares fell 22.73% to $2.21. The company's market cap stands at $98.8 million.
    • EUDA Health Holdings (NASDAQ:EUDA) shares fell 19.14% to $0.49. The company's market cap stands at $12.1 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares fell 18.26% to $0.66. The company's market cap stands at $2.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARDS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDS
    $BPTS
    $CVM
    $EUDA

    CompanyDatePrice TargetRatingAnalyst
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    Masimo Corporation
    $MASI
    11/17/2025Neutral
    BofA Securities
    Karyopharm Therapeutics Inc.
    $KPTI
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/16/2025Buy → Neutral
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    7/11/2025$27.00Buy
    H.C. Wainwright
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    Masimo Corporation
    $MASI
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    Masimo Corporation
    $MASI
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics

    Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight

    2/5/26 6:58:02 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Masimo

    BofA Securities initiated coverage of Masimo with a rating of Neutral

    11/17/25 9:40:41 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Karyopharm Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Karyopharm Therapeutics from Neutral to Buy and set a new price target of $15.00

    10/13/25 8:40:25 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

    SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC. Background of the Warrant As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and Januar

    3/4/26 9:10:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Masimo Corporation

    SCHEDULE 13G/A - MASIMO CORP (0000937556) (Subject)

    3/6/26 10:05:20 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    3/5/26 4:30:37 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    3/2/26 8:30:27 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Young Micah W was granted 15,000 shares and covered exercise/tax liability with 8,093 shares, increasing direct ownership by 38% to 25,254 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    3/3/26 8:29:38 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & Chief Commercial Officer Cheng Sohanya Roshan sold $43,321 worth of shares (4,604 units at $9.41), decreasing direct ownership by 4% to 107,317 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    3/3/26 4:27:11 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO&Secretary Mano Michael sold $33,178 worth of shares (3,526 units at $9.41), decreasing direct ownership by 4% to 93,964 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    3/3/26 4:28:39 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

    BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization of its mammography-based AI risk prediction platform and increasing engagement with health systems and partners worldwide. Clairity's innovation aligns with national priorities to improve health o

    1/21/26 4:30:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

    2/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARDS
    $BPTS
    $CVM
    $EUDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

    SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

    11/14/24 4:46:40 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/12/24 3:50:51 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care